What Analysts Recommend for Gilead Sciences in May 2017
In 1Q17, Gilead Sciences (GILD) reported revenues of ~$6.5 billion, a decline of ~17% on a year-over-year (or YoY) basis.
In 1Q17, Gilead Sciences (GILD) generated revenues of around $6.5 billion.
Gilead Sciences’ (GILD) HCV franchise was the company’s highest revenue-generating division back in 2015.
In 2016, Gilead Sciences’ (GILD) Truvada generated revenues of around $3.1 billion, reflecting ~3% year-over-year growth.
Gilead Sciences’ (GILD) tenofovir alafenamide fumarate (or TAF) based regimens have seen high adoption rates in the US and European markets.
In 1Q17, Gilead Sciences’ (GILD) Genvoya generated revenues of around $769 million. The drug has seen double-digit sequential sales growth in every quarter since its launch in November 2015.
Let’s look at Wall Street analysts’ recommendations and target prices for Boston Scientific (BSX) over the next 12 months.
Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.
On May 9, 2017, Boston Scientific (BSX) announced the FDA approval of its Resonate family of products, including its ICD and CRT-D systems.
Lotus Valve systems are Boston Scientific’s (BSX) TAVR (transcatheter aortic valve replacement) range of devices. The device system is approved to be sold in Europe.
On May 17, 2017, Boston Scientific (BSX) announced the completion of its acquisition of Symetis, which it announced on March 30, 2017.
Boston Scientific (BSX) was trading at $27.2 on May 25, 2017. It had a 50-day moving average of $25.8 and a 200-day moving average of $23.9.
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.
Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.
Sanofi Pasteur reported revenue growth of 22.2% at constant exchange rates to 784 million euros during 1Q17.
Sanofi Pasteur’s revenues rose 22.2 % at constant exchange rates to 784 million euros during 1Q17.
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.
Sanofi’s Diabetes and Cardiovascular franchise reported revenues of ~1.4 billion euros in 1Q17.
Paris-based Sanofi (SNY) reported revenues of ~8.7 billion euros in 1Q17. Sanofi surpassed analyst estimates, posting EPS of 1.42 euros in 1Q17, compared to estimates of 1.31 euros.
Abbott Laboratories (ABT) has projected its 2017 gross margin to be ~60%, higher than the 57.3% it reported in 2016.